What Evogene (EVGN) Said on Its Q3 Earnings Call

Evogene (NASDAQ:EVGN) reported a third-quarter net loss of approximately $2.9 million as revenue declined, while executives highlighted progress in two early-stage drug and agricultural chemical discovery programs.

The loss compared with net income of approximately $5.2 million a year earlier, when the company recognized income related to a transaction with ICL. Third-quarter revenue fell to approximately $0.1 million from $0.3 million, primarily because a license and collaboration agreement with Bayer concluded in May 2026, VP Finance Polina Ravzin said on the November 19 earnings call.

Evogene held approximately $9.2 million in consolidated cash, cash equivalents and short-term bank deposits as of September 30. Third-quarter cash usage was approximately $2.4 million, including a roughly $0.5 million directors and officers insurance payment covering 18 months.

Drug Program Targets Transplant Complication

President and CEO Ofer Haviv said Evogene is developing small-molecule candidates for acute graft-versus-host disease, a potentially serious complication of stem cell transplants in which donor immune cells attack the recipient’s tissues. The company announced the indication for its internal drug discovery program in October.

Haviv said the company used its ChemPass AI platform to generate novel molecular candidates over several months. Molecules tested so far showed biological potency at nanomolar concentrations and promising predicted preliminary absorption, distribution, metabolism, excretion and toxicology profiles, he said.

The CEO cautioned that the program remains at an early discovery and development stage and that candidates require further optimization and evaluation. Evogene is working toward studies needed to support an investigational new drug application.

In response to a question from AGP analyst Scott Henry, Haviv said Evogene expects to enter preclinical trials around the middle of 2027. He said that could be an opportunity to approach pharmaceutical companies with accumulated results and initial preclinical data about a potential partnership.

Dr. Corey Cutler of Dana-Farber Cancer Institute and Professor Dr. Robert Zeiser of University Medical Center Freiburg are providing scientific and clinical guidance for the program, Haviv said.

AgPlenus Advances Fungicide Candidates

Through its AgPlenus subsidiary, Evogene is also developing fungicides against Septoria, a wheat disease for which resistance to existing treatments is a growing challenge. The two discovery programs target fungal proteins that have not previously been used as targets for commercial fungicide development, according to Haviv.

Some molecules tested on infected plant tissue reduced disease severity by 75% compared with untreated controls, he said. Certain findings were independently validated by an external research organization, and testing also identified activity against other fungal pathogens.

AgPlenus plans further molecular optimization and biological testing before advancing leading candidates to greenhouse and field trials. Haviv said greenhouse testing could precede field trials, potentially in 2027, and that initial discussions had shown interest from potential partners.

Nine-Month Loss Widens

For the first nine months of 2026, Evogene’s revenue declined to approximately $0.8 million from $3.2 million a year earlier. Ravzin attributed the decrease mainly to lower revenue at Casterra, whose first-half 2025 results included approximately $2 million in seed sales.

The nine-month net loss widened to approximately $10.5 million from $2.5 million. Ravzin cited lower revenue, higher financing expenses and income recognized in connection with the ICL transaction in the prior-year period.

Net financing expenses were approximately $1.6 million for the nine months, compared with net financing income of approximately $0.9 million a year earlier. Ravzin said the change primarily reflected the accounting treatment and revaluation of warrants.

Third-quarter research and development expenses, net of nonrefundable grants, increased to approximately $1.5 million from $1.1 million. Ravzin said the prior-year figure was reduced by a grant and an adjustment to government-grant liabilities, with currency fluctuations also affecting the comparison.

About Evogene (NASDAQ:EVGN)

Evogene Ltd. is an Israel-based computational biology company founded in 2002. It uses its Computational Predictive Biology platform, which combines biological data, artificial intelligence and computational tools, to discover and develop products for agriculture, human health and other life-science applications. The company advances its work through subsidiaries and collaborations. Its businesses have included Casterra, which develops castor seed varieties, and Lavie Bio, which develops microbiome-based agricultural products.